Adherium introduces Hailie® technology into specialist US respiratory centres

Adherium Ltd (ASX:ADR) has signed an agreement with Monaghan Medical Corporation to support the introduction of its Hailie® asthma and respiratory treatment platform and technology into specialist respiratory centres in the United States. The agreement progresses Adherium’s refocused commercialisation plan targeting the estimated 1.5 million severe uncontrolled asthma and COPD (Chronic Obstructive Pulmonary Disease) patients where adherence is critical. These 1.5 million patients account for a significant healthcare burden due to the high cost of treatment and the company claims its technology has demonstrated a reduction in overall healthcare cost. “An important step” Adherium’s chief executive officer Mike Motion said: “This is an important step for Adherium with our Hailie® platform and sensors placed with customers and fully supported by Monaghan’s professional sales and clinical team. “We have worked closely with Monaghan and adapted our training programs, systems and support materials to meet patient needs and ensure alignment to Monaghan’s operational model. “Our technology will secure recurring revenue from sensor sales and data access which will enable Adherium with Monaghan to commercially address patients who are difficult to treat asthmatics and late-stage COPD patients of which there are more than 8 million in the US alone. “We are delighted to be working with Monaghan at this critical time for respiratory healthcare delivery and see their commercial support being highly complementary to the disease management activity provided by our partner HGE.” To pilot commercial program With feasibility testing and internal training already completed, Monaghan is planning the next phase which is to launch the pilot operational and commercial program. This phase will complete towards the end of the first quarter of 2021. The adoption of reimbursement for remote patient monitoring in the US has accelerated during COVID-19. Innovative value proposition Adherium and Monaghan believe there is an opportunity to strengthen differentiation with an innovative digital respiratory value proposition combining the Hailie® platform with Monaghan’s market-leading Aero-Chamber® in asthma and Aerobika® in COPD. The introduction of the Hailie® platform and technology will begin with eight specialist respiratory centres across six states in November as the precursor to wider commercialisation planned from Q2 calendar 2021. Monaghan Medical Corp president Gerald Slemko said: “This milestone reaffirms not just our partnership with Adherium, but also our mission to provide the finest, most researched and innovative products to the respiratory community. “In bringing this extended offering to our customers, we continue to build the Monaghan brand and further establish our position as market leaders.” Digital health solutions Adherium is a provider of digital health solutions and a global leader in connected respiratory medical devices, with more than 170,000 sold globally. Adherium’s Hailie® solution is designed to help patients achieve better adherence and provide visibility to parents and caregivers. It does this by tracking medication use and reminding the user with helpful nudges when it is time to take doses, and by providing access to usage history to better understand patterns in their asthma and COPD.